文献速递肿瘤 PET/CT神经核医学

68Ga-OPS202与68Ga-DOTATOC PET/CT在胃肠胰神经内分泌肿瘤患者中的敏感性比较:一项前瞻性II期影像研究

Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.
PubMed 文献 · J Nucl Med · 2017-11-30

本前瞻性II期研究纳入12例低或中级别胃肠胰神经内分泌肿瘤患者,比较68Ga-OPS202(生长抑素受体拮抗剂)与68Ga-DOTATOC(激动剂)PET/CT的敏感性。以增强CT或MRI为金标准,68Ga-OPS202 50μg和15μg的病灶总敏感性分别为94%和88%,均高于68Ga-DOTATOC 15μg的59%(P<0.001)。

要点

  • 68Ga-OPS202 50μg和15μg的病灶总敏感性分别为94%和88%,68Ga-DOTATOC 15μg为59%(P<0.001)。
  • 68Ga-OPS202两种肽剂量间图像对比度、敏感性和阳性预测值无显著差异。
  • 68Ga-OPS202与68Ga-DOTATOC的阳性预测值相似(约98%)。

核心结论

  • 本II期研究的初步诊断效能数据表明,68Ga-OPS202对胃肠胰神经内分泌肿瘤的检测具有高敏感性。
  • 原文结论提出需在更大患者群体中进一步研究。

研究设计与样本

  • 研究为I/II期研究中的II期部分,前瞻性纳入12例连续的低或中级别胃肠胰神经内分泌肿瘤患者。
  • 患者接受单次150 MBq静脉注射68Ga-DOTATOC(15μg肽)和两次单次150 MBq静脉注射68Ga-OPS202(第1次访视15μg肽,第2次访视50μg肽)。
  • 注射后1小时在同一台校准的PET/CT扫描仪上进行全身PET/CT采集,以增强CT或MRI为金标准,由两名独立设盲专家判读,两种判读结果合并分析。

主要发现

  • 匹配的恶性肝脏病灶图像对比度:68Ga-OPS202 15μg和50μg的平均肿瘤/本底SUVmax比值中位数分别为5.3(四分位距2.9-5.7,P=0.004)和4.3(四分位距3.4-6.3,P=0.008),均显著高于68Ga-DOTATOC的1.9(四分位距1.4-2.9)。
  • 病灶总敏感性:68Ga-OPS202 50μg为94%,15μg为88%,68Ga-DOTATOC 15μg为59%(P<0.001)。
  • 68Ga-OPS202 PET/CT与68Ga-DOTATOC PET/CT的阳性预测值相似(约98%)。
  • 68Ga-OPS202两种肽剂量间图像对比度、敏感性和阳性预测值无显著差异,表明具有高重复性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文结论提出需在更大患者群体中进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiolabeled somatostatin (sst) receptor agonists are integral to the diagnosis of gastroenteropancreatic neuroendocrine tumors (NETs), but detection rates, especially of liver metastases, remain limited even with PET/CT. 68Ga-OPS202 (68Ga-NODAGA-JR11; NODAGA = 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid and JR11 = Cpa-c(dCys-Aph(Hor)-dAph(Cbm)-Lys-Thr-Cys)-dTyr-NH2)), a novel radiolabeled sst receptor antagonist with a high affinity for the sst2 receptor, has the potential to perform better than sst receptor agonists. Here, we present the results of the phase II component of a phase I/II study that evaluated the sensitivity of 68Ga-OPS202, compared with the reference compound, 68Ga-DOTATOC (an sst receptor agonist), in PET imaging. Methods: Patients received a single 150-MBq intravenous injection of 68Ga-DOTATOC (15 μg of peptide) and 2 single 150-MBq intravenous injections of 68Ga-OPS202 (15 μg of peptide at visit 1 and 50 μg at visit 2). Whole-body PET/CT acquisitions were performed 1 h after injection on the same calibrated PET/CT scanner. Diagnostic efficacy measures were compared against contrast medium-enhanced CT or MRI as the gold standard. Two independent masked experts read the scans, and both outcomes were combined for analysis. Results: Twelve consecutive patients with low- or intermediate-grade gastroenteropancreatic NETs took part in this prospective study. Image contrast for matched malignant liver lesions was significantly higher for the 68Ga-OPS202 scans than for the 68Ga-DOTATOC scan: the median of the mean tumor-to-background SUVmax ratios were significantly higher for 15 and 50 μg of 68Ga-OPS202 (5.3 and 4.3, with interquartile ranges of 2.9-5.7 and 3.4-6.3 and P values of 0.004 and 0.008) than for 68Ga-DOTATOC (1.9, with an interquartile range of 1.4-2.9). The higher tumor-to-background ratio of 68Ga-OPS202 resulted not only in a higher detection rate of liver metastases but also in a significantly higher lesion-based overall sensitivity with the antagonist than with 68Ga-DOTATOC: 94% and 88% for 50 and 15 μg of 68Ga-OPS202, respectively, and 59% for 15 μg of 68Ga-DOTATOC (P < 0.001). Positive predictive values for 68Ga-OPS202 PET/CT and 68Ga-DOTATOC PET/CT were similar (∼98%). There were no significant differences in image contrast, sensitivity, or positive predictive values between the 2 68Ga-OPS202 peptide doses, indicating a high reproducibility. Conclusion: Preliminary diagnostic efficacy data from this phase II study indicate that 68Ga-OPS202 has high sensitivity for the detection of gastroenteropancreatic NETs. Further studies in larger patient populations are warranted.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Nicolas GP, Schreiter N, Kaul F, et al. Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study. J Nucl Med. 2017. PMID: 29191855. doi:10.2967/jnumed.117.199760

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。